George Drugs apoints Dr Charmaine Gittleson as a non-executive director

Londonn, United Kingdom, 12 July 2021 – George Medicines, an advanced drug development company focused on providing innovative and accessible medicines for the world’s leading causes of death, today announces the appointment of Dr Charmaine Gittleson to the Board of Directors as Director non-executive independent.

Dr Gittleson has extensive international experience as a pharmaceutical physician and business leader. Prior to joining the George Medicines Board of Directors, Dr Gittleson worked for ASX-listed global specialty biotechnology company CSL Behring, where she most recently served as Chief Medical Officer. During her 15-year tenure with the company, she held various leadership positions in clinical research, medical safety, medical and patient ethics, strategic product development, planning and implementation. works in multiple therapeutic areas and rare diseases.

Dr Gittleson has been a scientific speaker at several medical conferences and regulatory workshops (FDA and EMA), and a keynote speaker at the Women in Pharma & Leadership conferences for women working for ASX200 listed companies in 2017, 2018, 2019 and 2021.

She is a medical graduate with Bachelor of Science and Bachelor of Medicine and Surgery degrees from the University of the Witwatersrand, Johannesburg, South Africa. She also holds an Australian Medical Council qualification and is a graduate of the Australian Institute of Company Directors and the Stanford University Business Administration Course.

Professor Stéphane Mac Mahon, President by George Medicines, mentionned: “I am delighted to welcome Dr Gittleson to George Medicines at such an important time for our business as we progress Phase III development of GMRx2, our mnovel, Proprietary triple-dose and low-dose combination pill destined as first-line treatment for hypertension. Her the wealth of live, both as a physician and in management, will be priceless as we continue our mission to fight against non-communicable diseases, the leading causes of death and disability worldwide.“

Dr Charmaine Gittleson, Non-executive director of George Medicines, said: “I am delighted to join the George Medicines Board of Directors. With his platform single pill combination therapies, George Medicines has the potential to transform the lives of millions of people around the world. I can’t wait to workis lying with such an experienced management team to make their vision a reality. “

-Finish –

Contacts:

George Medicines
Stefan König, Managing Director
[email protected]

Strategic Communication Consilium
David Daley, Allison Connolly, Lindsey Neville
Phone: +44 (0) 203 709 5700
[email protected]

About George Medicines

George Medicines is an advanced-stage drug development company focused on improving the management of noncommunicable diseases through proprietary, innovative, single-pill combinations of existing drugs.

By combining best-in-class molecules from existing drugs into new fixed and low dose formulations, George Medicines is developing innovative and proprietary treatments that are more effective, safer and more affordable than currently available treatment options. These unique tablet combinations offer the potential for significant improvements in clinical outcomes and adherence in patients with cardiometabolic diseases such as heart disease, hypertension and diabetes, which remain the leading causes of death. premature and disability around the world.

George Medicines is building a strong and diverse pipeline of patented, single-pill combination therapies in advanced development. Following approval from the US Food and Drug Administration (FDA), its lead candidate, GMRx2, recently entered two phase III trials investigating its potential as an initial treatment for high blood pressure.

George Medicines is a spin-off company of the George Institute for Global Health, one of the world’s leading medical research institutes on noncommunicable diseases. The company is backed by George Health, the commercial arm of the George Institute, and Brandon Capital Partners, Australia’s leading biomedical venture capital firm, backed by the Australian government.

For more information, please visit www.george-medicines.com